Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


After The Anti-TNFs, What’s Next In Autoimmune Disease?

Executive Summary

With the threat of biosimilars looming closer, the leaders in autoimmune disease are scrambling to bring novel drugs to market and extend their dominance beyond the anti-TNF class. But toppling the anti-TNFs’ reign won’t be easy, especially if cheaper biosimilar copies reach the market.


Related Content

JAK1 Inhibitor From Galapagos Headed To Phase III – With Or Without AbbVie
Boehringer’s Home-Grown IL-23 Inhibitor Outperforms Stelara
IL-17: Pushing The Limits Of A Drug Target
Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into
Amgen’s Stealth Enbrel Patent May Block Biosimilars; Scenario May Apply To Other Biologics


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts